Diabetic Retinopathy and BDNF: A Review on Its Molecular Basis and Clinical Applications

Abstract EN

Impairment of neuroprotection and vasculopathy are the main reasons for the progression of diabetic retinopathy.

In this review, we decided to illustrate the molecular and clinical aspects of diabetic retinal neuro-vasculopathy.

We searched the Web of Science, PubMed, and Scopus databases with these keywords: “brain-derived neurotrophic factor” and “vascular endothelial growth factor” and/or “diabetic retinopathy.” The most relevant in vitro and clinical trial studies were then extracted for final interpretation.

Brain-derived neurotrophic factor and the vascular endothelial growth factor have pivotal roles in the pathogenesis of diabetic retinopathy.

They have neuroprotective effects on the retina.

However, there are controversial results on the relation between these two factors.

Reviewing available articles, we have concluded that various concentrations of these molecules at different stages of retinopathy may exert different effects.

Optimal doses of the brain-derived neurotrophic factor at the early stages of retinopathy may have a neuroprotective effect.

In contrast, higher concentrations of brain-derived neurotrophic factor might induce inflammatory responses.

Damage to the retinal cells due to metabolic alterations associated with diabetes and its consequence vasculopathy may also lead to changes in the ocular microenvironment and cytokines.

Changes in cytokines result in the modification of neural cell receptors and the overproduction of vascular endothelial growth factor.

It seems that controlling the optimal levels of neuroprotective molecules in the retinal tissue is the main step to halter diabetic retinopathy.